Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

about

Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.

P2860

Q47134647-40C8D3D4-A20A-444B-9CE3-1838E01C7AE6 Q52718920-5EB7B292-DA1B-4763-8560-5B5126829949 Q55398332-24162D1C-BA45-426B-B2D0-E6EA0D8B6B1D

P2860

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Item

http://www.wikidata.org/entity/Q47861831

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@en

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@nl

type

Item

label

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@en

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@nl

prefLabel

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@en

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@nl

P1476

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

@en

P2093

Alberto Verlicchi

http://www.w3.org/2001/XMLSchema#string

Alessandra Bulotta

http://www.w3.org/2001/XMLSchema#string

Chiara Lazzari

http://www.w3.org/2001/XMLSchema#string

Giuseppe Altavilla

http://www.w3.org/2001/XMLSchema#string

Maria Gonzalez-Cao

http://www.w3.org/2001/XMLSchema#string

Mariacarmela Santarpia

http://www.w3.org/2001/XMLSchema#string

Niki Karachaliou

http://www.w3.org/2001/XMLSchema#string

Vanesa Gregorc

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma

Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types

Toxicities of Immunotherapy for the Practitioner

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

P304

469-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17476348.2017.1326822

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Rosell

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28467720

http://www.w3.org/2001/XMLSchema#string

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

about

P2860

P2860

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698